SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine

Complete Genomics and SOPHiA GENETICS have announced a strategic collaboration to integrate the MSK-IMPACT and MSK-ACCESS precision oncology assays with the DNBSEQ-T1+ sequencing platform. This partnership combines AI-powered analytics from the SOPHiA DDM platform with high-throughput sequencing technology to provide an end-to-end, sample-to-report workflow for liquid biopsy and solid tumor research. By streamlining these complex genomic profiling tools, the companies aim to decentralize and scale precision medicine capabilities for laboratories and clinical researchers globally.

The collaboration centers on the integration of SOPHiA GENETICS’ AI-driven SOPHiA DDM platform and the Memorial Sloan Kettering-developed MSK-IMPACT and MSK-ACCESS assays onto Complete Genomics' newly launched DNBSEQ-T1+ sequencing system. Announced at the Association for Molecular Pathology (AMP) Annual Meeting, the joint offering is designed to provide a comprehensive workflow for laboratories looking to implement high-quality cancer genomic profiling. Rob Tarbox, vice president of product and marketing at Complete Genomics, noted that the pairing of MSK’s validated assays with SOPHiA’s analytics and their own sequencing technology enables decentralized labs to deliver faster and more affordable insights to clinicians and researchers.

The DNBSEQ-T1+ platform utilizes proprietary DNBSEQ technology to deliver Q40-level accuracy with a flexible throughput ranging from 500 million to 2 billion reads per flow cell. Each flow cell operates independently with a 24-hour paired-end 150bp run time, allowing for cost-effective scaling in precision oncology research. At maximum capacity, a single T1+ flow cell can process up to 60 tumor-normal tissue sample pairs or up to 16 tumor-normal liquid biopsy pairs. This technical efficiency is complemented by the SOPHiA DDM platform, which leverages AI to compute, standardize, and analyze complex healthcare data across a global network of institutions.

Joint evaluations of the MSK assays on the DNBSEQ-T1+ platform demonstrated highly concordant variant calls and allele frequencies when compared to existing sequencing systems. The integrated solution also achieved lower background noise and reduced turnaround times while maintaining seamless compatibility with existing SOPHiA DDM workflows. For the Genomics & Precision Medicine sector, this partnership represents a significant move toward making comprehensive genomic profiling more accessible to clinical laboratories, cancer centers, and drug developers. Ross Muken, President of SOPHiA GENETICS, emphasized that the collaboration supports the company’s mission to expand data-driven medicine through scalable, end-to-end genomic solutions, though the products are currently designated for research use only.